In the context of multi-peptide vaccination strategies, UV1 is a second-generation telomerase-based vaccine constituted by three hTERT-derived peptides (peptide 652–665, peptide 660–689 and peptide 691–705), which are the most frequently recognized by CD4+ T cells of long term cancer survivors, based on epitope spreading following vaccination with GV1001. This evidence concerns the gene CD4 and cancer.